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Abstract
Some human observational studies have suggested an anti‐inflammatory role of
osteocalcin (OCN). An inflammatory protocol using interferon‐γ and tumor necrosis
factor‐α (10 ng/ml) was employed to examine the acute (24 hr) and chronic (144 hr)
effects of uncarboxylated OCN (ucOCN) in commercial, primary, subcultured human
aortic endothelial cells (HAEC), and human smooth muscle cells (HASMCs). The
inflammatory protocol increased phosphorylation of intracellular signaling proteins
(CREB, JNK, p38, ERK, AKT, STAT3, STAT5) and increased secretion of adhesion
markers (vascular cell adhesion molecule‐1, intracellular adhesion molecule‐1,
monocyte chemoattractant protein‐1) and proinflammatory cytokines (interleukin‐
6 [IL‐6], IL‐8). After acute inflammation, there were no additive or reductive effects
of ucOCN in either cell type. Following chronic inflammation, ucOCN did not affect
cell responses, nor did it appear to have any pro‐ or anti‐inflammatory effects when
administered acutely or chronically on its own in either cell type. Additionally,
ucOCN did not affect lipopolysaccharide (LPS)‐induced acute inflammation in
HAECs or HASMCs. The findings of this study do not support a causal role for OCN
within the models of vascular inflammation chosen. Further confirmatory studies are
warranted.
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1 | INTRODUCTION
Atherosclerosis is a progressive inflammatory disease, involving
revolving phases of inflammation leading to macrophage infiltration
and microcalcifications (Hutcheson & Aikawa, 2014; Ross, 1999).
Inflammatory cytokines, chemoattractant proteins, and adhesion
molecules are present throughout the atherosclerotic process, of
which the endothelium and smooth muscle cell layers are both
pivotal. The process of atherosclerotic calcification is also crucially
triggered by inflammatory‐related pathways (Bessueille & Magne,
2015; Mazzini & Schulze, 2006). A paradox vascular‐bone axis exists
as while bone formation decreases with age, biomineralization of the
vasculature is increased, which is suggested to be due to a shared
etiology of inflammation (Bessueille & Magne, 2015; Sage, Tintut, &
Demer, 2010). The endocrine function of bone, particularly osteo-
calcin (OCN), is increasingly under investigation due to its link with
whole body metabolism and far‐reaching extra‐skeletal effects (Lee
et al., 2007; Oldknow, Macrae, & Farquharson, 2015; Oury et al.,
2011; Oury et al., 2013).
OCN is produced predominantly by osteoblasts and is the
most abundant, noncollagenous protein found in the mineralized
matrix of bone (Hauschka, Lian, & Gallop, 1975). Posttransla-
tional γ‐carboxylation of three glutamic acid residues within OCN
results in carboxylated OCN (cOCN). However, OCN can be
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carboxylated to varying degrees, allowing for undercarboxylated
forms to be present in the circulation (one or two carboxylated
residues), and uncarboxylated OCN (ucOCN; no carboxylated
residues). ucOCN has previously been regarded as the “active
form,” and it has less affinity to bind to hydroxyapatite crystals in
bone than cOCN.
Cross‐sectional observational studies in humans have demon-
strated inverse associations between OCN and systemic inflamma-
tory markers, such as C‐reactive protein (CRP) and interleukin‐6
(IL‐6; Bao et al., 2013; Chen et al., 2013; Liao et al., 2015; Lucey et al.,
2013; Pittas, Harris, Eliades, Stark, & Dawson‐Hughes, 2009; Sarkar
& Choudhury, 2013). A study including 108 newly‐diagnosed Type 2
diabetic patients reported that total serum OCN levels were
inversely associated with IL‐6 and CRP (Sarkar & Choudhury,
2013), these results were also evidenced in an older healthy
population (n = 380; Pittas et al., 2009). Two large studies in Chinese
males (n = 2,043 and n = 1,768) with metabolic syndrome or normal
metabolic state also found an inverse association between total
serum OCN and CRP (Bao et al., 2013; Liao et al., 2015). In young
obese and overweight women, as well as in postmenopausal women,
these findings have also been replicated (Lucey et al., 2013; Chen
et al., 2013). It is also known that subclinical inflammation is
associated with altered bone metabolism, which further potentiates a
role for OCN within the vasculature during inflammation (Ding,
Parameswaran, Udayan, Burgess, & Jones, 2008; Kim, Kim, & Sohn,
2010; Koh et al., 2005).
In white‐adipose tissue from ucOCN‐treated obese mice,
several inflammatory genes and transcription factors were down-
regulated including tumor necrosis factor (TNF); IL‐1β; IL‐6;
chemokine (C‐C motif) ligand, Ccl2; caspase 1; and NLR family,
pyrin domain containing 3, Nlrp3 (Guedes, Esteves, Morais, Zorn, &
Furuya, 2017). Within the same study, ucOCN‐treated (20 ng/ml)
mouse adipocytes similarly displayed a reduction in expression of
inflammatory genes following stimulation with TNF‐α (Guedes
et al., 2017).
OCN has previously been shown to increase nitric oxide
production and prevent free fatty acid‐induced apoptosis in human
aortic endothelial cells (HAECs); increase angiogenesis in a chick
embryo in vivo model; increase proliferation in HAECs and
HASMCs; and increase glucose metabolism and promote vascular
calcification in OCN‐over expressing mouse chondrocytes and
vascular smooth muscle cells (Cantatore, Crivellato, Nico, & Ribatti,
2005; Idelevich, Rais, & Monsonego‐Ornan, 2011; Jung et al., 2013;
Millar, Anderson, & O'sullivan, 2019). Interestingly, Hill et al. (2014)
demonstrated an anti‐inflammatory role of both cOCN and ucOCN
(20 ng/ml) in isolated rat adipocytes by decreasing TNF‐α secretion,
while cOCN also decreased IL‐6 secretion (Hill et al., 2014).
Furthermore, in whole tissue extracts, IL‐10 (an anti‐inflammatory
cytokine) was increased (Hill et al., 2014).
The potential role for OCN in the development of atherosclerosis
has been recently extensively reviewed (Tacey et al., 2018). The
question remains however whether OCN is a pathological bystander
or in fact mediator. To our knowledge, no in vitro studies to date
have investigated the inflammatory role of OCN in human vascular
cells. The aim of the current experiments was to investigate the
distinct role of ucOCN in HAECs and human aortic smooth muscle
cells (HASMCs) after acute and chronic administration, with and
without stimulated inflammation. We hypothesized that ucOCN may
reduce proinflammatory markers when administered on its own and
may reduce the stimulated inflammatory responses of HAECs and
HASMCs.
2 | MATERIALS AND METHODS
2.1 | Osteocalcin
Human ucOCN (amino acids 1–49, [Glu17,21,24]) was purchased
from AnaSpec Inc. CA (AS‐65307). The amino acid sequence of
purchased OCN was as follows: Tyr‐Leu‐Tyr‐Gln‐Trp‐Leu‐Gly‐Ala‐
Pro‐Val‐Pro‐Tyr‐Pro‐Asp‐Pro‐Leu‐Glu‐Pro‐Arg‐Arg‐Glu‐Val‐Cys‐Glu‐
Leu‐Asn‐Pro‐Asp‐Cys‐Asp‐Glu‐Leu‐Ala‐Asp‐His‐Ile‐Gly‐Phe‐Gln‐Glu‐
Ala‐Tyr‐Arg‐Arg‐Phe‐Tyr‐Gly‐Pro‐Val. The same batch of ucOCN has
been previously shown to be biologically active in vascular cells in
our previous work (Millar et al., 2019).
2.2 | Cell culture
HAECs and HASMCs were purchased from PromoCell (UK) and
maintained at 37°C in a humidified incubator supplemented with 5%
CO2. Cells were cultured in endothelial cell growth media and
smooth muscle cell growth media, respectively, containing 1%
penicillin–streptomycin (Sigma‐Aldrich, UK) and supplemental mix
(PromoCell, UK). In all experiments, cells were used between
passages 3 and 5. After experimental treatments, cell media was
collected and cells were washed once with phosphate‐buffered saline
(PBS; pH 7.4; Gibco™). Radioimmunoprecipitation buffer (Sigma‐
Aldrich) with protease and phosphatase inhibitors (A32959; Thermo
Fisher Scientific) was added to lyse the cells and the plates were
shaken at 4°C for an hour. The cells were then collected and
centrifuged at 14,000g for 5 min at 4°C and cell supernatants were
frozen at −80°C.
2.3 | Acute and chronic inflammation
Acute inflammation was induced by treating cells with 10 ng/ml
interferon‐γ (IFN‐γ) or vehicle (ethanol) for 8 hr, followed by addition
of 10 ng/ml TNF‐α or vehicle (1% ethanol) for 16 hr, as described
previously (Alhamoruni, Wright, Larvin, & O’sullivan, 2012). Cells
were cotreated with or without ucOCN (10 ng/ml; Hannemann et al.,
2013; Hu et al., 2013; Withold, Friedrich, & Degenhardt, 1997) for
24 hr in the acute inflammation protocol. The chronic inflammatory
protocol included 8 hr of IFN‐γ (5 ng/ml) followed by addition of
TNF‐α (5 ng/ml). After 48 hr, the media was replaced and treatment
repeated up until 144 hr. Cells were treated with or without ucOCN
(10 ng/mL). Media was collected at each time point and stored
at −80°C until analyzed.
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To test whether ucOCN could effect the production of
endogenously induced inflammation, in a subset of experiments,
lipopolysaccharide (LPS; 10 ng/ml) was added to HAECs and
HASMCs for 24 hr with and without ucOCN (10 ng/ml). Media
was collected after this time and stored at −80°C until analyzed.
2.4 | Total protein content
A bicinchoninic acid protein assay was performed to quantify the
total protein content in the cell lysates collected at the end of the
experiments (Smith et al., 1985).
2.5 | Cell signaling assay
The MILLIPLEX MAP 9‐plex Multi‐Pathway Magnetic Bead Signaling
Kit (catalog no. 48‐680MAG; Merck Millipore) was performed per
the manufacturers’ instructions to detect changes in phosphorylated
ERK/MAP kinase 1/2 (Thr185/Tyr187), AKT (Ser473), STAT3
(Ser727), JNK (Thr183/Tyr185), p70s6 kinase (Thr412), NFkB
(Ser536), STAT5A/B (Tyr694/699), CREB (Ser133), and p38
(Thr180/Tyr182) in cell lysates using the Luminex® xMAP® technol-
ogy (48‐680MAG; Milliplex™; Merck Millipore).
2.6 | Enzyme‐linked immunosorbent assays
Total OCN, endothelin pan specific, intracellular adhesion
molecule‐1 (ICAM‐1)/CD54, vascular cell adhesion molecule‐1
(VCAM‐1)/CD106, total MMP‐3, CCL2/monocyte chemoattractant
protein‐1 (MCP‐1), IL‐8/CXCL8, and IL‐17 DuoSet enzyme‐linked
immunosorbent assays (ELISA) were performed on cell culture
media as per the manufacturer’s instructions (catalog no. DY1419;
R&D systems, DY1160, DY720, DY809, DY513, DY279, DY208,
and DY317). IL‐6 ELISA Ready‐SET‐Go! was performed on cell
culture media as per the manufacturer’s instructions (catalog no.
88‐7066‐22; Affymetri; eBioscience).
2.7 | Lactate dehydrogenase activity assay
Lactate dehydrogenase activity (LDH) Colorimetric Assay kit (category
no. ab102526; Abcam) was performed on cell media from the chronic
inflammation experiment as per manufacturer’s instructions.
2.8 | Haematoxylin and eosin staining
After 48 hr of the chronic inflammation protocol, a representative
selection of HAECs and HASMCs was washed with PBS and fixed
with ice cold methanol/acetone (50:50) for 10min at room
temperature. Fixed cells were then washed with PBS and stained
with 0.1% Mayer’s haematoxylin and counterstained with 1% eosin
Y solution to allow visualization of the nuclei and cytoplasm.
2.9 | Statistical analysis
One‐way analysis of variances (ANOVAs) were performed to assess
differences in protein secretions and protein phosphorylation after
24 hr. Data were mostly normally distributed and nonparametric
t tests (Mann–Whitney) were performed in a few cases were the data
were not normalized. Results were normalized to protein content. Two‐
way ANOVAs were performed to detect differences in IL‐6 secretion
and LDH activity using time and treatment as factors for the chronic
inflammation experiment. Multiple comparisons were adjusted for by
Dunnett’s statistical hypothesis test. All statistical analyses were
performed using Prism 7 for Windows (Version 7.01; GraphPad
Software Inc.). p Values were considered significant at p < .05.
3 | RESULTS
3.1 | HAEC responses to acute OCN
No changes in protein secretions (VCAM‐1, IL‐8, ICAM‐1, IL‐10, IL‐6,
or MCP‐1) were observed in response to ucOCN in HAECs after
24 hr (Figure 1a–f). Furthermore, total protein content levels did not
differ between ucOCN and vehicle (Figure S1a). No intracellular
signaling protein phosphorylation (CREB, NFkB, p38, JNK, AKT, ERK,
STAT3, STAT5, or p70s6k) was affected by ucOCN (Figure 2a–i).
3.2 | HAEC responses to acute inflammation
Acute inflammation significantly increased the secretion of ICAM‐1,
VCAM‐1, IL‐6, IL‐8, and MCP‐1 (p < .001; Figure 1a,b,d–f). IL‐10
secretion was not affected (Figure 1c). Phosphorylation of CREB,
JNK, p38, ERK, AKT, STAT3, and STAT5 was increased with
inflammation (Figure 2a,b,d–f,h,i). Phosphorylation of NFkB and
p70s6k was not affected (Figure 2c,g). There were no significant
differences in cell signaling (CREB, p38, JNK, ERK, AKT, STAT3,
STAT5, NFkB, p70s6k), protein secretion, or total protein content
between cells treated with or without ucOCN alongside inflammation
after 24 hr.
3.3 | Human aortic endothelial cell responses to
chronic OCN
In the chronic experiments, IL‐6 secretion increased over time but was
not affected by OCN (10 ng/ml) after 48, 96, or 144 hr incubation
(Figure 3a). Similarly, no effects of ucOCN were observed on LDH
activity, IL‐10 secretion, or total protein content (Figure 3c–f).
3.4 | Human aortic endothelial cell responses to
chronic inflammation
Because we found no anti‐inflammatory effects of ucOCN in the acute
inflammatory protocol, we next established whether any effects
become apparent after prolonged inflammation and ucOCN treatment.
IL‐6 secretion increased over time with the inflammatory protocol, with
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a peak observed at 48 hr, but ucOCN demonstrated no additional
affects (Figure 3b). Nicotinamide adenine dinucleotide H concentration
was measured as an indicator of LDH activity. LDH activity increased
sharply following 48 hr of inflammation in HAECs, following a similar
trajectory as with IL‐6 production (Figure 4d). There were no
differences detected between cells treated with ucOCN alongside
inflammation and those treated with inflammation alone (Figure 3d).
IL‐10 secretion at 144 hr did not differ between treatment groups
F IGURE 1 Protein secretion responses in HAECs after acute inflammation. Mean % change relative to vehicle and SEM of secreted cell
proteins VCAM‐1, ICAM‐1, IL‐6, endothelin, IL‐10, IL‐8, and MCP‐1 when treated with vehicle, ucOCN (10 ng/mL), an inflammatory protocol
(IFN‐γ and TNF‐α, both 10 ng/ml, 8 hr followed by 16 hr, respectively), or inflammatory protocol and ucOCN. Data were normalized to total
protein content. Data were analyzed by one‐way ANOVA. **** indicates p < .001 compared with vehicle. HAEC, human aortic endothelial cell;
ICAM‐1, intracellular adhesion molecule‐1; IL, interleukin; inflm, inflammatory protocol; MCP‐1, monocyte chemoattractant protein‐1; ucOCN,
uncarboxylated osteocalcin; SEM, standard error of mean; VCAM‐1, vascular cell adhesion molecule‐1
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(Figure 3e). Total protein content (as an indicator of cell death) was
decreased with the inflammatory protocol (p < .05) but no additional
effect of ucOCN was observed (Figure 3f).
After 48 hr of inflammatory protocol, HAECs adopted an
activated, spindle‐shaped morphology as opposed to the character-
istic cobblestone appearance of noninflamed cells (Figure S2).
3.5 | HASMC responses to acute OCN
No changes were observed in the secretion of ICAM‐1, IL‐8, MCP‐1,
IL‐17, MMP‐3, or endothelin after 24 hr treatment with ucOCN
compared with vehicle (Figure 4a–f). Phosphorylation of p38, ERK,
AKT, CREB, JNK, NFkB, p70s6k, STAT3, and STAT5 was not affected
by ucOCN exposure (Figure 5a–i). Total protein content did not differ
with ucOCN treatment (Figure S1B).
3.6 | HASMC responses to acute inflammation
ICAM‐1, MCP‐1, IL‐8, and MMP‐3 secretion was significantly
increased by inflammation in HASMCs compared to vehicle
(p < .001), however no effect of ucOCN was observed
(Figure 4a–c,e). There was no significant effect of inflammation
F IGURE 2 Intracellular signaling responses in HAECs. Luminex® xMAP® technology was used to detect changes in phosphorylated CREB (pS133),
JNK (pT183/pY185), NFkB (pS536), p38 (pT180/pY182), ERK (pT185/pY187), Akt (pS473), p70 S6K (pT412), STAT3 (pS727), and STAT5A/B (pY694/
699; 48‐680MAG; Milliplex™; Merck Millipore) in cell lysates when treated with vehicle or ucOCN (10ng/ml) with and without inflammatory stimulus
(IFN‐γ and TNF‐α) for 24 hr. Data were analyzed by one‐way ANOVA with multiple comparisons to vehicle corrected for by Dunnett’s test. Data are
given as means with error bars representing SEM. *denotes a significant difference compared with vehicle (*p< .05. **p< .01, ***P< .005, ****p< .001).
HAEC, human aortic endothelial cell; IFN‐γ, interferon‐γ; inflm, inflammatory protocol (8 hr of IFN‐γ 10 ng/ml followed by addition of TNF‐α 10 ng/mL
for 16 hr); SEM, standard error of mean; TNF‐α, tumor necrosis factor‐α; ucOCN, uncarboxylated osteocalcin
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nor OCN on endothelin production or IL‐17 secretion (Figure 4d,f).
Phosphorylation of CREB, p38, ERK, and STAT3 was increased
with inflammation but no additional effect of ucOCN was
observed (Figure 5a–i).
3.7 | HASMC cell responses to chronic OCN
In the chronic experiments, IL‐6 secretion increased over time but
was not affected by OCN after 48, 96, or 144 hr incubation
(Figure 6a). LDH activity increased over time, with no additional
effect of ucOCN observed (Figure 6c). Similarly, IL‐10 secretion
and total protein content was not affected by OCN after 144 hr
(Figure 6e,f).
3.8 | HASMC responses to chronic inflammation
Following chronic exposure to inflammation, IL‐6 secretion increased in
HASMCs until 96 hr and remained elevated (Figure 6b). Addition of
ucOCN did not affect IL‐6 levels. Similarly, LDH activity was increased
with inflammation but was not affected by the coadministration of
ucOCN (Figure 6d). IL‐10 and total protein content were not altered by
the inflammation protocol nor ucOCN (Figure 6e,f).
3.9 | OCN secretion is not detected following
chronic inflammation
Finally, total OCN was measured in cell media after chronic
inflammation (144 hr) to test whether inflammation induced OCN
F IGURE 3 IL‐6 secretion, LDH activity, IL‐10 secretion, and total protein content in HAECs after chronic inflammation with or without OCN. The
effects of ucOCN on secretion of IL‐6 without inflammation (a) and with inflammation (b) after 0, 48, 96, and 144hr. The effect of ucOCN on LDH
activity was measured by NADH concentration without inflammation (c) and with inflammation (d) after 0, 48, 96, and 144hr. IL‐10 secretion was
measured after 144hr (e). Total protein content was measured by BCA assay at the end of the experiment. ucOCN (10 ng/ml) was added every 48 hr.
Total n=9 from three experimental repeats. Data are given as means with error bars representing SEM. *denotes a significant difference compared with
vehicle, analyzed by one‐way ANOVA (**p< .01, ***p< .005). ANOVA, analysis of variance; HAEC, human aortic endothelial cell; IL, interleukin; IFN‐γ,
interferon‐γ; inflm, inflammatory protocol (8 hr of IFN‐γ followed by addition of TNF‐α; both 5 ng/ml); LDH, lactate dehydrogenase; NADH, nicotinamide
adenine dinucleotide H; SEM, standard error of mean; TNF‐α, tumor necrosis factor‐α; ucOCN, uncarboxylated osteocalcin
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F IGURE 4 Protein secretions in HASMCs after acute inflammation. Mean % change relative to vehicle and SEM of secreted cell proteins
ICAM‐1, MCP‐1, endothelin, MMP‐3, IL‐17, and IL‐8 when treated with vehicle, ucOCN (10 ng/ml), an inflammatory protocol (IFN‐γ and TNF‐α,
both 10 ng/ml, 8 hr followed by 16 hr, respectively), or inflammatory protocol and ucOCN. Data were normalized to total protein content. Data
were analyzed by one‐way ANOVA. ****denotes a significant difference compared with vehicle (p < .005). ANOVA, analysis of variance; HASMC,
human aortic smooth muscle cell; ICAM‐1, intracellular adhesion molecule‐1; IL, interleukin; IFN‐γ, interferon‐γ; MCP‐1, monocyte
chemoattractant protein‐1; MMP‐3, matrix metalloproteinase; SEM, standard error of mean; TNF‐α, tumor necrosis factor‐α; ucOCN,
uncarboxylated osteocalcin; inflm, inflammatory protocol
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secretion. OCN was not detectable in media from HAECs nor
HASMCs at the end of the experiments (data not shown).
3.10 | OCN does not prevent LPS‐induced
inflammation
As ucOCN did not affect inflammation induced by exogenously added
cytokines, we then tested whether LPS‐induced inflammation elicited
a different response. Acute LPS treatment (24 hr) significantly
increased secretion of VCAM‐1 and ICAM‐1 in HAECs and HASMCs,
respectively, compared with control (Figure 1c,d). In both HAECs and
HASMCs, there were no differences in VCAM‐1 or ICAM‐1 secretion
respectively between LPS treated and LPS + ucOCN‐treated cells
(Figure 1c,d).
4 | DISCUSSION
OCN is synthesized predominantly by osteoblast cells, which acts as
an extra‐skeletal hormone known to effect insulin sensitivity, insulin
F IGURE 5 Intracellular signaling responses in HASMCs. Luminex® xMAP® technology was used to detect changes in phosphorylated CREB
(pS133), JNK (pT183/pY185), NFkB (pS536), p38 (pT180/pY182), ERK (pT185/pY187), Akt (pS473), p70 S6K (pT412), STAT3 (pS727), and
STAT5A/B (pY694/699; 48‐680MAG; Milliplex™; Merck Millipore) in cell lysates when treated with vehicle or ucOCN (10 ng/ml) with and
without inflammatory stimulus (IFN‐γ and TNF‐α) for 24 hr. Data were analyzed by one‐way ANOVA with multiple comparison to vehicle
corrected for by Dunnett’s test. Data are given as means with error bars representing SEM. *denotes a significant difference compared with
vehicle (*p < .05. **p < .01, ***p < .005, ****p < .001). ANOVA, analysis of variance; HASMC, human aortic smooth muscle cell; IFN‐γ, interferon‐γ;
inflm, inflammatory protocol (8 hr of IFN‐γ 10 ng/ml followed by addition of TNF‐α 10 ng/ml for 16 hr); SEM, standard error of mean; TNF‐α,
tumor necrosis factor‐α; ucOCN, uncarboxylated osteocalcin
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secretion, energy metabolism, cognition, and fertility (Lee et al.,
2007; Oury et al., 2011; Oury et al., 2013). Population‐based cross‐
sectional studies have reported a negative or inverse association
between OCN and markers of systemic inflammation, such as IL‐6
and CRP, suggesting a potential anti‐inflammatory role (Chen et al.,
2013; Kim et al., 2010; Liao et al., 2015; Pittas et al., 2009; Sarkar &
Choudhury, 2013; Schett et al., 2006). However, the in vitro effects
of OCN on inflammation within the vasculature have not yet been
described. Therefore, we decided to try and reveal mechanisms of
action of ucOCN during inflammation, as well as investigate the
effects of acute and chronic administration of ucOCN on its own.
Here, we demonstrate for the first time using two human vascular
cell types that ucOCN does not regulate or alter the inflammatory
responses of HAECs or HASMCs during acute inflammation. Our
observational results presented here do not reflect an anti‐inflammatory
role of OCN suggested by some cross‐sectional, human studies, at least
within the experimental models used. ucOCN did not affect inflammatory
cytokine production nor inflammatory signaling pathways in HASMCs
and HAECs. This may be representative of the nonbinary nature of OCN
which cannot be limited to having a positive or negative influence overall
in vascular pathology and physiology in humans. It may transpire that
OCN plays a protective role in the later stages of atherosclerosis and
have more of an impact on the process of calcification.
As no overall anti‐inflammatory effects of OCN were reported in
the acute inflammatory protocol, we next established whether any
effects of OCN become apparent after prolonged inflammation and
OCN treatment. Pro‐ and anti‐inflammatory cytokine production as
well as LDH activity were not affected by chronic ucOCN treatment,
alone or in combination with the inflammatory protocol. Lastly, we
further showed that in another model of inflammation using LPS,
F IGURE 6 IL‐6 secretion, LDH activity, IL‐10 secretion, and total protein content in HASMCs after chronic inflammation with or without
OCN. The effects of ucOCN on secretion of IL‐6 without inflammation (a) and with inflammation (b) after 0, 48, 96, and 144 hr. The effect of
ucOCN on LDH activity was measured by NADH concentration without inflammation (c) and with inflammation (d) after 0, 48, 96, and 144 hr.
IL‐10 secretion was measured after 144 hr (e). Total protein content was measured by BCA assay at the end of the experiment. ucOCN (10 ng/ml)
was added every 48 hr. Total n = 9 from three experimental repeats. BCA, bicinchoninic acid; HASMC, human aortic smooth muscle cell; LDH,
lactate dehydrogenase; IFN‐γ, interferon‐γ; IL, interleukin; inflm, inflammatory protocol (8 hr of IFN‐γ followed by addition of TNF‐α; both 5 ng/ml);
NADH, nicotinamide adenine dinucleotide H; TNF‐α, tumor necrosis factor‐α; ucOCN, uncarboxylated osteocalcin
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ucOCN did not affect VCAM‐1 or ICAM‐1 secretion in HAECs and
HASMCs respectively. An interesting observation from this study
was the transition of HAECs after 48 hr of chronic inflammation to an
activated morphology that is characteristic of endothelial cells under
sheer stress and inflammation, representative of the early stages of
atherosclerosis (Hunt & Jurd, 1998). This corresponds to the
upregulation of activated endothelium markers VCAM‐1 and
ICAM‐1 reported at 24 hr. Additionally we demonstrated that
inflammation does not induce secretion of OCN itself.
The role of OCN in cardiovascular disease has had conflicting results
in humans. Some longitudinal studies have reported U‐shaped associa-
tions between OCN and cardiovascular‐related or all‐cause mortality
(Kanazawa, Yamaguchi, & Sugimoto, 2011; Yang et al., 2017; Yeap et al.,
2012). However, other studies have found no association between OCN
and cardiovascular disease risk (Holvik et al., 2014; Hwang et al., 2015). A
systematic review and meta‐analysis on the association between OCN
and markers of atherosclerosis or calcification in humans found no
conclusive relationship (Millar, Patel, Anderson, England, & O’sullivan,
2017). Although a causal role of ucOCN in vascular inflammation was not
identified in this study, further work should explore whether OCN may
influence systemic inflammation via directly acting on immune cells.
Additionally, the exploration of the possible biological activity of other
forms of circulating OCN should not be disregarded. We recognize that
phenotypic drift occurs with the isolation and subculturing of cells and
we acknowledge this as a limitation of the current study. Further work
should explore both the effect of OCN on intact vessels and on cells from
different vascular beds including resistance and conduit vessels.
In conclusion, in our models of vascular inflammation, OCN did
not display a role in the direct inflammatory responses of primary
subcultured HAECs or smooth muscle cells in either an acute or
chronic setting.
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